SSY GROUP (02005): Metronidazole has been approved by the National Pharmaceutical Regulatory Authority for registration as an active pharmaceutical ingredient for use in marketed preparations.
Shisi Pharmaceutical Group (02005) announced that the Group's metronidazole has been approved for registration by the China National Medical Products Administration...
SSY GROUP (02005) announced that the group's metronidazole has been approved by the China National Medical Products Administration for registration as an active pharmaceutical ingredient used in marketed formulations. Metronidazole is a nitroimidazole antibiotic, mainly used to treat appendicitis and pelvic inflammatory disease caused by anaerobic bacteria.
Related Articles
Attractive valuation + promising growth prospects: UBS Group AG upgrades CVS Health (CVS.US) to "buy" rating.
Bank of America Securities: Reiterate JD HEALTH (06618) with a "buy" rating and hold a more optimistic view on the company's prospects.
Goldman Sachs: XTEP INT'L (01368) mid-term net profit exceeds expectations, slightly raised target price to 7.1 Hong Kong dollars.
Attractive valuation + promising growth prospects: UBS Group AG upgrades CVS Health (CVS.US) to "buy" rating.
Bank of America Securities: Reiterate JD HEALTH (06618) with a "buy" rating and hold a more optimistic view on the company's prospects.
Goldman Sachs: XTEP INT'L (01368) mid-term net profit exceeds expectations, slightly raised target price to 7.1 Hong Kong dollars.
RECOMMEND
Former Innovative Pharma Star Faces Growing Pains—Why Zai Lab’s Stock Tumbled Despite Strong Results
18/08/2025
World Humanoid Robot Games In-Depth: Competition Drives Technological Innovation and Accelerates Industry Progress
18/08/2025
Guangdong Cross-Border E-Commerce: Tariff Pressures Spur Overseas Warehouse Boom as Sellers Target Russia and Latin America
18/08/2025
